Abraxis Bioscience Inc. trades on the “NASDAQ” under the Stock Symbol”ABII”. For the Latest information regarding “ABII”, make sure to visit the Most Exclusive and In Depth newsletter website at: …
Merriman Curhan Ford downgrades Abraxis BioScience (Nasdaq: ABII) from Buy to Neutral ... The only positive is the stock trades with an enterprise value of approximately $1.2B, or 3.8 times 2009 annualized …
Many value investors look for stocks with a high percent of insider ownership, under the theory that when management are shareholders, they will act in its own self interest, and create shareholder value in the long …
Insider
Celgene (CELG) will buy Abraxis BioScience (ABII) in a cash-and-stock deal that values the firm at $2.9B, marking a 17% premium to Abraxis' closing price yesterday. The purchase gives Celgene access to Abraxis' …
The Dow Jones Industrial Average DJIA, +0.07% was largely flat at 9,882. Abraxis Bioscience ABII was the stock of note in early trading. Shares of the biotech group shot up over 20% to $74.39 on news that Celgene Corp. …
He is one of an estimated 35,000 people in the United States who will die from pancreatic cancer this year ... Abraxis with a "Buy" rating and a price target range of $30-$33. The stock is lightly traded because the …
In the third line + setting of the MBC market, ABRAXANE had a 49.7 percent share of the taxane market. This excerpt taken from the ABII 8-K filed May 7, 2009. According to recent IntrinsiQ data for March 2009, in all …
Biotechnology company Celgene (CELG) announced it is buying Abraxis BioScience (ABII) for $2.9 billion in cash and stock. With this acquisition, Ceglene is expanding its portfolio of cancer treatments. Abraxis shareholders …
AOL6y
She, however, warned that this offer would be treated on a first come first served basis and subject to availability of stock. Speaking on the CTO 2005 Abii explained that in keeping with tradition, Zinox was partnering with …